Wedbush analyst Liana Moussatos reiterated a Buy rating on Pacira Pharmaceuticals (NASDAQ:PCRX) on Tuesday, setting a price target of $93, which is approximately 46.43% above the present share price of $63.51.
Moussatos expects Pacira Pharmaceuticals to post earnings per share (EPS) of $0.33 for the second quarter of 2021.
The current consensus among 12 TipRanks analysts is for a Strong Buy rating of shares in Pacira Pharmaceuticals, with an average price target of $84.67.
The analysts price targets range from a high of $94 to a low of $72.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $130.97 million and a net profit of $25.55 million. The company's market cap is $2.79 billion.
According to TipRanks.com, Wedbush analyst Liana Moussatos is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 9.8% and a 43.66% success rate.
Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.